Related Experiment Video
Updated: Aug 9, 2025
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
Guijin Tang1, Dawei Wang1, Xiangqian Zhao1
1Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Qishan Campus, Fujian Normal University, College Town, Fuzhou 350117, China.
Abstract:
Oncolytic viruses (OVs) have emerged as effective gene therapy and immunotherapy drugs. As an important gene delivery platform, the integration of exogenous genes into OVs has become a novel path for the advancement of OV therapy, while the herpes simplex virus type 1 (HSV-1) is the most commonly used. However, the current mode of administration of HSV-1 oncolytic virus is mainly based on the tumor in situ injection, which limits the application of such OV drugs to a certain extent. Intravenous administration offers a solution to the systemic distribution of OV drugs but is ambiguous in terms of efficacy and safety. The main reason is the synergistic role of innate and adaptive immunity of the immune system in the response against the HSV-1 oncolytic virus, which is rapidly cleared by the body's immune system before it reaches the tumor, a process that is accompanied by side effects. This article reviews different administration methods of HSV-1 oncolytic virus in the process of tumor treatment, especially the research progress in intravenous administration. It also discusses immune constraints and solutions of intravenous administration with the intent to provide new insights into HSV-1 delivery for OV therapy.
Insights
Herpes simplex virus type 1 (HSV-1) oncolytic viruses show promise for cancer therapy. This review explores intravenous administration challenges and solutions for improved systemic delivery and efficacy.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Immunotherapy
Background:
- Oncolytic viruses (OVs) are effective gene therapy and immunotherapy agents.
- Herpes simplex virus type 1 (HSV-1) is a common platform for OV development.
- Current HSV-1 OV administration is primarily via intratumoral injection, limiting broader application.
Purpose of the Study:
- To review administration methods for HSV-1 oncolytic viruses in cancer treatment.
- To focus on advancements and challenges in intravenous administration of HSV-1 OVs.
- To discuss immune system constraints and potential solutions for effective intravenous delivery.
Main Methods:
- Literature review of HSV-1 oncolytic virus administration strategies.
- Analysis of research progress in intravenous delivery of OVs.
- Examination of immune responses impacting HSV-1 OV efficacy and safety.
Main Results:
- Intratumoral injection is the primary administration route for HSV-1 OVs.
- Intravenous administration offers systemic distribution but faces challenges with immune clearance.
- Immune responses rapidly eliminate HSV-1 OVs before reaching tumors, causing side effects.
Conclusions:
- Intravenous administration of HSV-1 OVs requires strategies to overcome immune-mediated clearance.
- Addressing immune constraints is crucial for enhancing the efficacy and safety of systemic OV therapy.
- Further research into HSV-1 delivery methods can optimize OV-based cancer treatment.
